PAVmed Inc. (PAVM) company profile
Close on Nov 17, 2026Market cap $12.07MP/E –Yield –
About PAVmed
Surgical & Medical Instruments & Apparatus, SIC 3841
PAVmed Inc. is a diversified commercial-stage life sciences company operating across medical devices, diagnostics, and digital health through a shared services structure. Its diagnostics subsidiary, Lucid Diagnostics, provides the EsoCheck cell collection device and EsoGuard DNA test to detect esophageal precancer in at-risk patients with gastroesophageal reflux disease. Its digital health unit, Veris Health, delivers the Veris Cancer Care Platform and VerisBox connected devices for continuous physiological monitoring and remote symptom reporting during cancer treatment. In addition, the company develops medical devices, including the PortIO implantable intraosseous vascular access device and licensed endoscopic imaging technology. Customers and distribution channels include gastrointestinal specialists, primary care doctors, health systems, self-insured employers, unions, and cancer centers.
The company operates physical Lucid Test Centers in major metropolitan areas, uses satellite testing sites in physician clinics, and serves VA hospitals nationwide. It maintains an order fulfillment and packaging facility in Foxborough, Massachusetts, alongside a clinical laboratory in Lake Forest, California. The text does not disclose the location of its corporate headquarters.
Summary of the business section of PAVmed's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PAVmed Inc.
- Founded
- 2014
- Headquarters
- New York, NY
- Address
- 360 Madison Avenue, 25th Floor 10017
- Phone
- (212) 949-4319
- Website
- pavmed.com
- Employees
- 3, Dec 31, 2016
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Marcum LLP, New York, NY
Stock & identifiers
- Ticker
- PAVM
- Former tickers
- PAVMU until Nov 10, 2016
- Exchange
- Nasdaq
- IPO date
- Jan 29, 2016
- Shares outstanding
- 8M, Aug 13, 2026
- Public float
- $11.80M, Jun 30, 2024
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-30 reverse, Jan 2, 2026; 1-for-15 reverse, Dec 7, 2023
- SEC CIK
- 1624326
- CUSIP
- 70387R502
- ISIN
- US70387R5028
- FIGI
- BBG00DGWP2L8
- Share class FIGI
- BBG00DGWP3H1
- LEI
- 549300V1JXXVXU7P8007
- EIN
- 47-1214177
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lishan Aklog | Chairman and CEO, Director | 367,573 |
| Victoria Tou-ho Lee | Chief Medical Officer | 1,666 |
| Dennis M. McGrath | President and CFO | 196,195 |
| Shaun O'Neil | Chief Operating Officer | 115,598 |
| Michael Adam Gordon | General Counsel | 115,000 |
| Michael J. Glennon | Director | 21,653 |
| Debra White | Director | 21,097 |
| Timothy E. Baxter | Director | 21,097 |
| Ronald M. Sparks | Director | 21,097 |
| Sundeep Agrawal | Director | 19,337 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $1.03M | $992.47K | $595.77K | $3 | – |
| FY2024 | $1.37M | $798.31K | $1.09M | $2 | – |
| FY2023 | $953.20K | $882.53K | $627.33K | $11 | – |
| FY2022 | $1.63M | -$2.03M | $1.34M | $20 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|
| Lishan Aklog, M.D. Chairman of the Board and Chief Executive Officer (3) | $613.00K | $306.50K | $64.65K | $50.70K | $1.03M | +56% |
| Dennis M. McGrath President and Chief Financial Officer (4) | $438.00K | $153.30K | $64.65K | $11.10K | $667.05K | +49% |
| Shaun M. O’Neil Chief Operating Officer (5) | $325.00K | $81.25K | $64.65K | $11.10K | $482.00K | +43% |
| Michael A. Gordon General Counsel and Secretary (6) | $450.00K | $112.50K | $64.65K | $11.10K | $638.25K | +38% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 29, 2016
- Securities offered
- 1,200,000
- Exchange
- Nasdaq
- First trading day
- Jul 27, 2016
- First-day close
- $5.00
- Lock-up ends (est.)
- Jan 23, 2017
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We have three employees and four executive officers, two of whom are also members of our Board of Directors.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?